Having trouble accessing articles? Reset your cache.

IDX184: Development hold

FDA placed a clinical hold on HCV candidates IDX184 and IDX320 due to 3 serious adverse events in a Phase I drug-drug interaction study of the

Read the full 262 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE